The global effort to eradicate type 1 diabetes (T1D) has long been a marathon of precision science, advocacy, and strategic investment. However, as the complexity of the disease reveals itself through genomic mapping and advanced immunology, organizations like Breakthrough T1D (formerly JDRF) have recognized that victory requires more than just established expertise—it requires a continuous infusion of "fresh eyes" and multidisciplinary perspectives. In the summer of 2026, Breakthrough T1D’s Research department welcomed a select group of interns whose work has already begun to reshape the organization’s strategic approach to business development, clinical trials, and global screening.
n
Main Facts: The Strategic Integration of New Talent
n
Breakthrough T1D’s mission is singular: to accelerate life-changing breakthroughs that lead to a world without T1D. This mission is operationalized through a robust Research Program that identifies scientific gaps, fosters long-term relationships with global investigators, and invests in the most promising therapeutic avenues.
n
The 2026 internship program was designed not as a peripheral educational exercise, but as a core component of the Research department’s operational capacity. This year’s cohort consisted of five high-level graduate and doctoral-track students specializing in biotechnology, public health, biostatistics, and medicine. Their projects were specifically curated to address high-priority "blind spots" within the T1D landscape, ranging from the historical mapping of clinical evidence to the standardization of islet cell manufacturing data.
n
By integrating these interns into the Research Business Development, Cell Therapy, and Early Detection teams, Breakthrough T1D has effectively leveraged academic rigor to solve institutional challenges. The results of these internships—including new databases, visualization tools, and policy frameworks—are now being utilized by senior leadership to direct future funding and research priorities.
n
Chronology: A Summer of Iterative Discovery
n
The 2026 summer program followed a rigorous timeline of immersion, research, and synthesis. The cycle began in early June with an intensive orientation where interns were paired with senior mentors, including Racquel Enad, MS, MPH, and Nicholas Mamrak, Ph.D.
n
Phase I: Immersion and Identification (June)nDuring the first month, interns were tasked with deep-diving into the T1D research landscape. This involved reviewing decades of organizational data and identifying specific areas where information was fragmented or outdated. For example, Kenzie Li began her ambitious project of mapping clinical T1D evidence spanning half a century, while Jihyun Park audited the Industry Development and Discovery Partnerships (IDDP) program’s 22-year history.
n
Phase II: Data Synthesis and Stakeholder Engagement (July)nBy mid-summer, the interns moved from literature reviews to active data generation and stakeholder interviews. Aliaa Elkallini, working with the Cell Therapy team, conducted interviews with investigators to understand the practical challenges of islet characterization. Simultaneously, Avi Patel launched a global survey of international screening programs to identify disparities in early detection methodologies.
n
Phase III: Final Reporting and Implementation (August)nThe program culminated in a series of executive-level presentations. Interns presented their findings to the Research department and senior leadership, providing actionable recommendations. These were not merely academic exercises; they were strategic briefings that influenced how Breakthrough T1D views its global funding footprint and its clinical trial accessibility.
n
Supporting Data: Project Outcomes and Technical Contributions
n
The impact of the 2026 cohort is best understood through the specific, data-driven tools and frameworks they developed during their tenure.
n
1. Business Development and Industry Mapping
n
Jihyun Park, a biotechnology master’s student at Columbia University, addressed a critical need for longitudinal tracking within the Research Business Development and Partnerships team. Since 2004, the IDDP program has been a cornerstone of Breakthrough T1D’s venture philanthropy model. Park developed a comprehensive database of IDDP company grantees, tracking milestones such as subsequent financings, clinical progress, and industry partnerships.
n
- n
- Key Output: A visualization tool that maps the interconnectedness of IDDP companies within the broader T1D industry, allowing the team to measure the "multiplier effect" of Breakthrough T1D’s initial investments.
n
n
2. Global Funding Landscapes
n
Sophia Meininger, a dual degree student in Global Public Health and Africana Studies at Binghamton University, focused on the "geography of innovation." Her project mapped the global funding landscape for T1D research, with a specific emphasis on emerging research ecosystems in underserved regions.
n
- n
- Key Output: A strategic report identifying leading institutions and investigators in developing research hubs, providing a roadmap for international collaborations that transcend traditional Western-centric funding models.
n
n
3. Standardization in Cell Therapy
n
Aliaa Elkallini, an M.D. candidate at the CUNY School of Medicine, tackled the "reproducibility crisis" in manufactured islet research. Because different labs use different metrics to characterize islets, comparing data across studies is notoriously difficult.
n
- n
- Key Output: Two complementary frameworks for islet characterization. The first establishes the "minimum information" required for clear reporting, while the second provides a sliding scale of expectations based on a study’s specific goals (e.g., pilot vs. pivotal).
n
4. Early Detection and Screening Gap Analysis
Avi Patel, an MPH candidate at LIU Brooklyn and a former dentist, utilized her epidemiological background to analyze the global T1D screening landscape.
- Key Output: A comparative analysis of international screening programs against clinical consensus guidelines. Her work identified significant gaps in how screening is implemented across different healthcare systems, providing the foundation for a more unified global screening strategy.
5. Clinical Trial Accessibility
Kenzie Li, studying Biostatistics and Data Science at Weill Cornell Medicine, applied her analytical skills to the human side of research. She analyzed the barriers and facilitators faced by clinical trial participants.
- Key Output: A data visualization suite illustrating participant-centered trial design. Furthermore, she initiated a "Historical Evidence Map" (1975–2026) to pinpoint exactly where T1D research evidence is missing or has become obsolete over the last 50 years.
Official Responses: Mentorship and Organizational Philosophy
The leadership at Breakthrough T1D views the internship program as a symbiotic relationship. It is not merely a service to the students, but a vital intellectual refresh for the organization.
"The summer interns bring a fresh perspective and creativity to their projects, giving us a better understanding of T1D and how to advance our mission," explained Matt Whipple, an Analyst in Research Strategy and one of the program’s mentors. Whipple emphasized that the interns often ask "why" in ways that challenge long-held institutional assumptions, leading to more innovative problem-solving.
Racquel Enad, MS, MPH, Senior Manager of Research Partnerships & Alliances, highlighted the importance of the intergenerational exchange of ideas. "Making progress toward our mission requires us to stay innovative, analytical, and open to learning," Enad stated. "Training the next generation is important not only because we can help develop future leaders, but because we learn from them too. That exchange of ideas, perspectives, and curiosity helps move us closer to breakthroughs in T1D."
The mentorship model at Breakthrough T1D ensures that interns are not working in silos. Each project is overseen by a Senior Scientist or Manager, ensuring that the work is grounded in current scientific reality while allowing the intern the freedom to explore new methodological approaches.
Implications: Building the Pipeline for a Cure
The long-term implications of the 2026 internship program extend far beyond the summer months. By investing in these five individuals, Breakthrough T1D is effectively seeding the future of the T1D workforce with experts who already have a deep, nuanced understanding of the organization’s goals.
Workforce Development: The interns—representing the fields of medicine, public health, biostatistics, and biotechnology—are now equipped to become the next generation of T1D advocates and researchers. Sophia Meininger’s lived experience with T1D, combined with her new expertise in funding landscapes, positions her as a future leader in health equity and advocacy. Similarly, Aliaa Elkallini’s work in cell therapy standardization will likely influence her future career as a physician-scientist.
Data-Driven Strategy: The tools developed by Jihyun Park and Kenzie Li provide Breakthrough T1D with a "digital memory." By having a clear map of past clinical evidence and industry partnerships, the organization can avoid redundant funding and pivot more quickly toward high-potential, under-researched areas.
Global Coordination: Avi Patel’s and Sophia Meininger’s projects have provided a framework for a more internationalized approach to T1D. As the disease affects populations globally, the ability to coordinate screening and research across borders is essential. Their work ensures that Breakthrough T1D remains the central hub of a truly global network.
In conclusion, the 2026 Research Internship Program at Breakthrough T1D demonstrates that the path to a cure is not built solely on laboratory experiments, but on the rigorous analysis of data, the optimization of clinical systems, and the continuous cultivation of new talent. As these five interns return to their respective universities, they leave behind a stronger, more informed organization—and they carry with them the energy and expertise needed to eventually bring the era of type 1 diabetes to an end.
